CC
SAGE

Chicago Capital’s Sage Therapeutics SAGE Stock Holding History

Chicago Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-91,051
Closed -$12.8M – 222
2019
Q3 		$12.8M Buy
91,051
+17,612
+24% +$2.95M 0.86% 45
2019
Q2 		$13.4M Buy
73,439
+416
+0.6% +$71K 0.86% 45
2019
Q1 		$11.6M Buy
73,023
+41,850
+134% +$6.06M 0.79% 47
2018
Q4 		$2.99M Buy
+31,173
New +$3.57M 0.24% 61

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Chicago Capital's SAGE Position: Q4 2019 in Review

Chicago Capital sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 91,051 shares — an estimated $12.8M sold.

Chicago Capital first reported a position in SAGE in Q4 2018 and held it in 4 quarters. The position peaked at $13.4M in Q2 2019. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • Chicago Capital reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Chicago Capital sold 91,051 Sage Therapeutics shares in Q4 2019, an estimated $12.8M.
  • Chicago Capital first reported a position in Sage Therapeutics in Q4 2018 and held it in 4 quarters.
  • Chicago Capital's Sage Therapeutics position peaked at $13.4M in Q2 2019.
  • 266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Chicago Capital's 13F filing for Q4 2019, filed 14 Jan 2020.